SUMMARY: Treponema pallidum, hepatitis C virus (HCV), human immunodeficiency virus (HIV)-1, and hepatitis B virus (HBV) are major causes of sexually transmitted diseases passed through blood contact. The development of a sensitive and efficient method for detection is critical for early diagnosis and for large-scale screening of blood specimens in China. This study aims to establish an assay to detect these pathogens in clinical serum specimens. We established a TaqMan-locked nucleic acid (LNA) realtime polymerase chain reaction (PCR) assay for rapid, sensitive, specific, quantitative, and simultaneous detection and identification. The copy numbers of standards of these 4 pathogens were quantified. Standard curves were generated by determining the mean cycle threshold values versus 10-fold serial dilutions of standards over a range of 10 6 to 10 1 copies/mL, with the lowest detection limit of the assay being 10 1 copies/mL. The assay was applied to 328 clinical specimens and compared with enzyme-linked immunosorbent assay (ELISA) and commercial nucleic acid testing (NAT) methods. The assay identified 39 T. pallidum-, 96 HCV-, 13 HIV-1-, 123 HBV-, 5 HBV/HCV-, 1 T. pallidum/HBV-, 1 HIV-1/HCV-, and 1 HIV-1/T. pallidum-positive specimens. The high sensitivity of the assay confers strong potential for its use as a highly reliable, cost-effective, and useful molecular diagnostic tool for largescale screening of clinical specimens. This assay will assist in the study of the pathogenesis and epidemiology of sexually transmitted blood diseases.
INTRODUCTION
Blood transfusion is a life-saving therapy, and its provision and safety are often taken for granted in the industrialized world (1) . The demand for blood is driven by an array of conditions that include obstetric hemorrhage, road traffic accidents, armed conflict, sickle cell disease, childhood anemia, malnutrition, human immunodeficiency virus (HIV), malaria, and parasitic infections (2) .
Transfusion safety relating to blood-transmissible agents is a major public health concern (1) . Treponema pallidum and HIV-1 are major causes of sexually transmitted blood diseases. Hepatitis B and C viruses (HBV and HCV, respectively) are also common pathogens of transfusion-transmitted diseases. These infections pose serious global and national public health problems. Clinically, they usually co-infect patients, especially in high-risk populations. Furthermore, in blood transfusions and organ transplantations, it is of great importance to avoid the transmission of these pathogens to the recipient. Methods currently used for detection include serological testing and immunological testing bioassays, polymerase chain reaction (PCR) and fluorescent quantitative real-time PCR (3, 4) . The mandated blood screenings in China are serological tests for HBV surface antigens, antibodies against T. pallidum, HCV, and HIV-1 (5) .
Although the mandate for serological screening is important in improving donation selection to reduce the risk of transfusion-transmitted infections, it remains limited during the pre-seroconversion window period (PWP) as well as in cases of immunosilent infections, as the tests only provide positive results once the donor's immune system reacts against the respective pathogens (3,4,6-11). Among chronically transfused recipients, the HBV prevalence as measured by HBsAg presence is 33z, while the prevalence in the blood donor population is 1.2z (12) , and the prevalence of HCV in thalassemics as measured by anti-HCV presence is 57z, while the prevalence in the blood donor population is 0.4z (13) . These data are among the growing evidence that serological screening of infectious blood misses some infectious units during the PWP (14) .
In order to decrease the risk of pathogens transmission, especially from individuals who are in the PWP at the time of blood or plasma donation, nucleic acid testing (NAT) methods have been included in detection methods; nucleic acids are propagated prior to serological markers and therefore shorten the infectious PWP. As the goal of NAT is to identify infection cases falsely detected by serological assays, higher standards should be set for the sensitivity of NAT systems (15) . As a result, the most advanced technique, real-time PCRbased NAT, has been developed to reduce this risk (10, 16) . Additionally, the results of real-time PCRbased NAT are available immediately, and further processing or handling of the specimens is not required (17) . The multicolor detection technology permits the simultaneous monitoring of up to 6 amplifications in a single well and allows for the separation of the signals according to each fluorophore.
At present, a number of commercial real-time NAT assays are available for simultaneous detection (18, 19) . However, none of the NAT assays match China's legal requirements for blood screening.
China has also observed a remarkable increase in other sexually transmitted diseases in the past 2 decades because of changing social values and sexual behaviors (20, 21) . Besides the increase in the incidence of HCV, HIV-1, and HBV, the reported incidence (1/100,000) of syphilis rose to 64.41 in 2009 (22) . As a result, China has declared the control of sexually transmitted diseases as one of its highest priorities in the management of epidemic diseases. Consequently, the routine detection of T. pallidum, HCV, HIV-1, and HBV has been recently included in hematological test-based diagnosis in China.
In an effort to further improve methods for the detection of these pathogens from donated blood and organs in China, our present work aims to develop a multiplex real-time RT-PCR assay that would allow for the rapid, sensitive, specific, economic, quantitative and simultaneous detection and identification of the sexually transmitted blood pathogens T. pallidum, HCV, HIV-1, and HBV.
MATERIALS AND METHODS
Viral and bacterial standards: Standard HIV-1 genome plasmid PNL-43 and plasmids containing the 5 ? -UTR sequence of HCV 1b, pre-S sequence of HBV, and poly-A sequence of T. pallidum isolated from clinical specimens were included in this study (3, 4) . These reference plasmids were used as templates for conventional PCR, which were sequenced after cloning.
Three additional blood-transmitted virus strains (HTLV-1, hepatitis A virus, and hepatitis E virus) were obtained from the China National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China) and 3 additional sexually transmitted bacterial strains (Ureaplasma urealyticum, U. parvum, Chlamydia trachomatis) were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA). These 6 strains were cultured in vitro and collected for nucleic acid extraction as templates for comparison and reference purposes to test the specificity of our multiplex real-time RT-PCR assay for the specific detection of T. pallidum, HCV, HIV-1, and HBV.
Clinical isolates and specimens: The major subtypes of endemic pathogens causing syphilis, viral hepatitis, or AIDS in China are as follows: clinically isolated T. pallidum pallidum strain; HCV subtypes 1a, 1b, and 2a; HBV subtypes B, C, D, and C/D recombinant; and HIV-1 subtypes Thai-B, CRF07/08_BC, and CRF01_ AE. We obtained all the clinically isolated pathogen subtypes mentioned above from Hubei International Travel Healthcare Center; subtypes were determined by sequencing. To mimic the co-infection specimens, pathogens were matched out in pairs and diluted in pathogen-free serum from healthy donors for further use. These pathogens are the most prevalent endemic pathogens in China: the T. pallidum pallidum strain, HCV 1b, HBV subtype C, and HIV-1 subtype Thai-B.
Both pathogen (from patients) and pathogen-free (from health donors) serum specimens were collected from the Hospital affiliated to Wuhan University and the Hubei Provincial Hospital of Traditional Chinese Medicine. All these serum specimens were confirmed in the laboratory by analysis with enzyme-linked immunosorbent assay (ELISA) methods (KHB, Shanghai, China) or NAT methods (HCV and HBV, Shenzhen PG Biotech Co., Ltd, Shenzhen, China). All specimens were aliquoted and stored at -809 C (3, 4) .
Primers and TaqMan-locked nucleic acid (LNA) probe design: We used degenerate primers and TaqMan-LNA probes to detect T. pallidum, HCV, HIV-1, and HBV spontaneously. To confirm the identity of the corresponding gene fragments, the nucleotide sequences, primers, and TaqMan-LNA probes used were queried against the GenBank nucleotide database using BLASTN. Primers and probes were designed to correspond to highly conserved regions of genomes in these pathogens using Beacon Designer software Version 7.0 (Palo Alto, CA, USA). However, there were still some nucleotide differences due to mutations in these pathogens. We therefore included degenerate bases to ensure that the assay could be used to simultaneously cover most genotypes of these pathogens. The sequences of the primers and TaqMan-LNA probes used in this study are listed in Table 1 .
Probes were labeled with Eclipse at the 3? end and 4 different fluorescent reporter dyes (ROX, FAM, TET, and CY5) at the 5?end, so that the 4 different pathogens could be detected simultaneously in a single tube according to the different emission wavelengths of the dyes. Because of the high AT content of the target regions, dual labeled LNA probes were chosen to enhance the melting temperature; LNA nucleotides were denoted in capital letters. All of the primers were synthesized by Shanghai Invitrogen Biotechnology (Shanghai, China) and all of the dual labeled TaqMan-LNA probes were produced and modified by TaKaRa (TakaRa Biotechnology [Dalian] CO., LTD., Liaoning, China).
Nucleic acid isolation: Nucleic acids of clinical serum specimens (200 mL) were extracted using the AxyPrep TM Body Fluid Viral DNA/RNA Miniprep Kit (Axygen Scientific Inc, Union City, CA, USA) according to the manufacture's protocol. Bacterial strains (U. urealyticum, U. parvum, C. trachomatis) and virus strains (HTLV-1, hepatitis A virus, and hepatitis E virus) were mixed with 200 mL serum from healthy donor separately and then were processed for nucleic acid extraction by the AxyPrep TM Body Fluid Viral DNA/RNA Miniprep Kit. Nucleic acids were eluted from the filter column with 60 mL of nuclease-free double-distilled water.
Multiple real-time RT-PCR: (i) Preparation of DNA plasmid standard: The specific target segments of T. pallidum and HBV were amplified, cloned into a PTA-2 vector, propagated in E.coli DH5a, and identified as 
Real-Time PCR Assay for Blood Safety Detection previously described by Cao et al. (17) . Plasmids were purified with a QIAamp plasmid Midi Kit (Qiagen, Valencia, CA, USA). Plasmid DNA was eluted and stored at -809 C and concentrations were measured by UV absorbance at 260 nm and 280 nm using an ultraviolet spectrophotometer (UV-2102PC, UNICO Instruments, Co., Ltd., Shanghai, China).
The copy number of the extracted plasmids was calculated using the formula: DNA copy number (copies/mL) ＝ DNA concentration (g/mL) × 6.02 × 10 23 (copies/ mol) ÷ plasmid length (bp) ÷ 660 (g/mol). (ii) Preparation of cRNA transcript standard: Fragments containing the target regions of the assays were amplified from HIV-1 genome plasmid PNL-43, and plasmids containing the 5?-UTR sequence of HCV 1b with primers containing a T7 promoter sequence on the reverse side were transcribed in vitro using a T7 RiboMAX TM Large Scale RNA Production System (Promega, Madison, WI, USA). The synthetic cRNA transcripts were then purified and quantified using a UV absorbance method (23, 24) . The copy number of cRNA standards was calculated using the following formula: RNA copy number (copies/mL) ＝ RNA concentration (g/mL) × 6.02 × 10 23 (copies/mol) ÷ RNA length (nt) ÷ 345 (g/mol). (iii) Multiplex real-time RT-PCR assay: The multiplex real-time RT-PCR assay was performed using a Mx4000 multiplex quantitative PCR system (Stratagene CO., La Jolla, CA, USA) as recommended by the manufacturer in a 50 mL reaction system. The reaction system contained 1 mL nucleic acid, 1×PCR buffer (pH 8. Sci&Tech CO., LTD, Shanghai, China) were also added and finally distilled water was used to bring the final volume to 50 mL in 3 separate RNase-free PCR tubes.
Cycling condition were as follows: 509 C for 30 min, followed by PCR activation at 949 C for 10 min, and 40 cycles of amplification at 959 C for 30 s, and 589 C for 60 s. Negative controls were included in each analytical procedure. The multiple fluorescence signals of ROX, FAM, TET, and CY5 were measured once per cycle at the end of the 589 C step. For each dye, the analysis of fluorescence data was conducted using Mx4000 software (Version 4.2; Stratagene Co., La Jolla, CA, USA). The threshold fluorescence level, used to derive Ct values was determined automatically by the Mx4000 software.
Standard curves of multiplex real-time RT-PCR assay: To construct standard curves, 10-fold serial dilutions of the DNA and cRNA standards spanning 1×10 6 to 10 1 copies/mL were used and tested in triplicate. Standard curves were plotted as the mean Ct values versus the log copy numbers.
Assay sensitivity, specificity, and reproducibility: To determine the detection limit, 1 × 10 6 to 101 copies/mL of the standard DNA and cRNA were amplified under the optimum conditions with 1 mL of each standard per reaction. The results for each concentration were obtained by fluorometric analysis.
The specificity of this assay was evaluated by performing the assay on China's major endemic pathogen subtypes and 6 different pathogens (HTLV-1, HAV, HEV, U. urealyticum, U. parvum, C. trachomatis) as well as a negative control (specimens from healthy donors).
The DNA and cRNA standards, including 10 2 , 10 4 , and 10 6 copies/mL were assayed to evaluate the interassay and intra-assay reproducibility. Each concentration was analyzed in triplicate. The threshold cycle of each concentration was obtained and calculated.
Ethics statement: Written informed consent was ob- tained from all study participants, sera specimens were collected from the study subjects. The study was carried out in strict accordance with the requirements for clinical studies established by the Wuhan University, China.
RESULTS
Standardization and sensitivity of multiplex real-time RT-PCR assay: The detection limit was determined to be 10 1 copies/mL for each pathogen. The threshold cycles (Ct), including 10 1 copies/mL in each pathogen, were 34.44, 34.92, 34.62, and 34.68 for T. pallidum, HCV, HIV-1, and HBV, respectively, and the lengths of the amplicons were 103 bp, 110 bp, 147 bp, and 100 bp respectively. The linear correlations (R 2 ) between the threshold cycle and the copy logarithm were 0.998, 0.996, 0.998, and 0.999. As expected, every 10-fold decrease in the copy number resulted in an approximately 3.3-unit increase in the Ct-value. In addition, statistical analysis of each standard curves revealed a high correlation coefficient and a high PCR efficiency between the Ct-value and the standard DNA/cRNA in all standards (Fig. 1) . These results suggested that the multiplex realtime RT-PCR assay that we designed was suitable for the genomic quantification when 4 pathogens were simultaneously present in the same tube.
Specificity of multiplex real-time RT-PCR assay: This assay was highly specific for detecting T. pallidum, HCV, HIV-1, and HBV. Six additional reference pathogens (HTLV-1, hepatitis A virus, and hepatitis E virus, U. urealyticum, U. parvum, and C. trachomatis) and the template-free control (DEPC-treated water) were not amplified (Fig. 2) . However, China's major endemic pathogen subtypes (the T. pallidum pallidum strain; HCV subtypes 1a, 1b, and 2a; HBV subtypes B, C, D, and C/D recombinant; and HIV-1 subtypes Thai-B, CRF07/08_BC, and CRF01_AE) could all be detected by this assay.
To determine the influence of pathogens when they co-infected, we mimicked this situation ex vivo, and measured the Ct for each pathogen. We found that the Ct values of T. pallidum pallidum were 24.65 ± 0.74, 26.01 ± 0.91, or 25.36 ± 1.07 when present with HCV, HIV-1, or HBV, while the Ct value of T. pallidum palli- Real-Time PCR Assay for Blood Safety Detection dum alone was 25.12 ± 0.42. There was no significance among these 4 situations. There was also no significance when we came to measure the Ct values of HCV 1b, HIV-1 Thai-B, or HBV subtype C respectively (Table  2 ). These results confirmed that the performance of the assay is very stable when measuring either 1 or 2 of these pathogens spontaneously in 1 reaction.
Intra-and inter-assay variations:
The reproducibility of multiplex real-time RT-PCR assay was established using the Ct values that were obtained from testing standards in triplicate within each run (intra-assay) and in 3 different runs (inter-assay). The coefficient of variation (CV) of T. pallidum for the threshold cycle values ranged between 0.45z and 0.90z for the intra-assay and 1.09z and 1.6z for inter-assay. The CV for intraassay and inter-assay of HCV ranged between 0.45z and 0.75z and between 2.21z and 2.24z, receptivity. The CV for intra-assay and inter-assay of HIV-1 ranged between 0.48z and 1.67z and between 1.18z and 3.04z, respectively. Finally, the CVs for intra-assay and inter-assay of HBV ranged between 0.31z and 1.48z and between 1.61z and 2.19z, respectively (Table 3). These results confirmed that the performance of the assay is very stable and reproducible.
Assay performance on clinical specimens: To evaluate and demonstrate the usefulness of the assay for clinically detecting T. pallidum, HCV, HIV-1, and HBV specimens, we compared these results to the results gathered using ELISA and NAT real-time PCR using the same clinical specimens. A total of 328 clinical specimens were analyzed and our results showed that the positive rate of detection of the assay was 82.62z (271 of 328) ( Table 4 ). In contract, the total positive rates of the ELISA and NAT real-time PCR were 65.24z (214 of 328) and 51.83z (170 of 328), respectively. In our study, of 271 positive clinical specimens, 11.89z (39 of 328) contained only T. pallidum; 29.27z (96 of 328) contained only HCV; 3.96z (13 of 328) contained only HIV-1; and 37.5z (123 of 328) contained only HBV. Furthermore, 0.30z (1 of 328) contained both T. pallidum and HBV (abbreviated as T. pallidum/HBV); 1.52z (5 of 328) contained both HBV and HCV (HBV/HCV); 0.30z (1 of 328) contained both HIV-1 and HCV (HIV-1/HCV); and 0.30z (1 of 328) contained both HIV-1 and T. pallidum (HIV-1/ T. pallidum) (Table 4) .
Accurate copy numbers of all the 271 single pathogen-positive specimens were automatically calculated according to the standard curves. Among the T. pallidum, HCV, HIV-1 or HBV single-positive specimens, 0, 31, 0, and 23 were in the range of 10 1 to 10 3 copies; 39, 15, 0, and 11 were in the range of 10 3 to 10 5 copies; and 0, 50, 13, and 89 were over 10 5 copies. For 8 double-positive specimens, both pathogens of 3 HBV/ HCV specimens were in the range of 10 1 to 10 3 copies, HCV were 10 1 to 10 3 or 10 3 to 10 5 copies and HBV were 10 3 to 10 5 copies for another 2 HBV/HCV specimens; HBV was 10 1 to 10 3 copies and T. pallidum was 10 3 to 10 5 copies for 1 HBV/T. pallidum specimen; HCV or T. pallidum was 10 3 to 10 5 copies and HIV-1 were over 10 5 copies for HIV-1/HCV and HIV-1/ T. pallidum respectively (Table 5) .
DISCUSSION
Compared with traditional methods such as RT-PCR, ELISA, IFA, and virus isolation, real-time RT-PCR has the advantage of being faster and more sensitive (25, 26) . As a result, such assays have been developed recently and have quickly become one of the most important methods for pathogen detection.
Using real-time RT-PCR, several fluorophores can be measured in 1 tube and multiplex assays can be performed; therefore, it can be used to detect different target sequences simultaneously in 1 reaction (12) . Its superior analytical capacity is seen especially when the detection of several possible pathogens is needed in a short period of time. Its ability to perform tests in parallel rather than sequentially also makes it a suitable alternative to traditional methods. The simultaneous detection of various pathogens has often been addressed by multiplex PCR (27, 28) .
The development of such a multiplex real-time RT-PCR assay was very challenging, because a combination of the optimized primer pairs and probes and optimal ion concentrations were required for the detection of each target pathogen. Indeed, more attention must be paid to the design and optimization of the reaction system. In this study, we established and evaluated a multiplex real-time RT-PCR assay for the simultaneous detection of T. pallidum, HCV, HIV-1, and HBV. The multiplex real-time RT-PCR assay was sensitive enough to detect 10 copies of the pathogen genome and it yielded an excellent linear range between 10 6 and 10 1 copies of standard DNA/cRNA. Furthermore, its high specificity was confirmed by the positive signals obtained from China's major endemic subtypes. There were no significant differences in Ct values during detection of a pathogen from either single-positive or double positive specimens (Table 2 ). In addition, negative signals were obtained from 6 other related pathogens that show no cross-reactivity among the selected pathogens that cause sexually transmitted diseases. Furthermore, this assay had high reproducibility. The mean CVs of the interand intra-assay variation were all ＜5z (Table 3) , which is considered acceptable.
Quantification of pathogen nucleic acids is very important to determine the burden of infection with respect to pathogenic potential. In this study, standard curves were established based on the serial dilutions of T. pallidum, HBV DNA and HCV, HIV-1 cRNA standards, which was the key step to mimic the pathogen nucleic acid in vitro. To construct cRNA standards, the designed primer pairs were modified with a T7-promoter sequence at the 5 ? -end of the forward primer and with an oligo-(dT) at the 5?-end of the reverse primer according to the method described by Totzke et al. (23, 24) . The use of these primer pairs ensured that the nucleotide sequences of the HCV and HIV-1 cRNA standards were identical to those in the HCV and HIV-1 genome. This method for the construction of cRNA standards is simple and suitable to measure the transcripts of any genes of interest.
The entire course of the detection including pathogen genome nucleic acid extraction and the qPCR test took approximately 2 and a half hours, making it a fast and simple assay. When this assay was applied for detection in 328 clinical specimens, it identified 39 T. pallidumpositive, 96 HCV-positive, 13 HIV-1-positive, and 123 HBV single-positive specimens. The results of this assay were consistent with results obtained from the same specimens using ELISA or NAT methods. The multiplex real-time PCR assay was more sensitive and effective, and it showed much higher specificity and coverage. Using these clinical specimens, we also confirmed more HBV-or HCV-positive specimens by this assay than we did by the NAT or ELISA methods. It is important to note that during the development of disease caused by blood-borne viruses, mutations will occur in the viral genome. As a result, it was necessary to upgrade the primers and/or probes for real-time detection, especially based on the genome sequences of local epidemic strains. We anticipated this mutational issue and provided a solution by designing the primers and probes based on the latest epidemiologic pathogen sequences in China. Furthermore, this assay is highly efficient and economical. Of the specimens, we found that 1 was identified as T. pallidum/HBV positive, 1 was HIV-1/HCV positive, 1 was HIV-1/ T. pallidum and in total 5 were HBV/HCV double positive among these real-time PCR-positive specimens, which were spontaneously tested only in 1 reaction. Therefore, this assay was able to detect pathogens from peripheral blood even during PWP, making it more suitable for early clinical diagnosis.
The multiplex real-time RT-PCR assay developed in the present study is a rapid and highly specific technique for the detection of pathogens in blood. In comparison to traditional methods, multiplex real-time RT-PCR assays could reduce concerns about false-negatives, increase efficiency significantly, and help reduce expenses when a large number of blood specimens are processed. As we mainly focused on whether infections are not detected by serological assays, we only needed to label the 4 probes with the same common fluorescent reporter dye at the 5?end. This assay would provide a very useful molecular diagnostic tool for large-scale screening of clinical specimens, especially at the time of safety screening of donated blood; it will also assist in the study of the pathogenesis and epidemiology of sexually and blood-transmitted diseases.
